Prolactin antagonists and uses thereof
AssigneeThe Regents of the University of California
InventorAMEAE M. WALKER
Life of this patent
Estimating the term…
Abstract
Recombinant nucleotide sequences encoding mutated prolactin are described. Expression of the sequences result in mimics of a phosphorylated prolactin corresponding to a selected species. A particularly preferred mimic is mutated at serine 179 (corresponding to human PRL) where serine is substituted by an aspartate residue. This aspartate mutant is a very effective antagonist and shows no ability to stimulate Nb2 to cell proliferation.
Claims13
A recombinant nucleotide sequence encoding a mutated prolactin, wherein the expression of the sequence results in a mimic of a phosphorylated prolactin corresponding to a selected species, the mimic being capable of antagonizing growth promoting effects of non-phosphorylated prolactin in the selected species, the mimic being mutated at serine 179 or its selected species equivalent.
A recombinant nucleotide sequence encoding a prolactin mutant, wherein the expression of the sequence results in a mimic of human phosphorylated prolactin, the mimic being capable of antagonizing a prolactin receptor, the mimic being mutated at serine 179 or its selected species equivalent.
A composition comprising:
- a human phosphorylated prolactin mimic, the mimic in an amount effective to antagonize growth promoting effects of non-phosphorylated human prolactin, the mimic being mutated at serine 179 and being substantially free of non-phosphorylated human prolactin.
Dependencies are inferred from the claim text.